Specific indicators of unsuitability for transarterial chemoembolisation in patients with intermediate-stage hepatocellular carcinoma according to thresholds of tumour burden and liver function as judged by survival benefit over sorafenib
Hong Kong Medical Journal · 2025
DOI: 10.12809/hkmj2311239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hong Kong Medical Journal, 2025. Verfasst von L M Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Imaging and Interventional Radiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Sorafenib, Liver Neoplasms, Chemoembolization, Therapeutic. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Imaging and Interventional Radiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
- Department of Medical Ultrasonics, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
- State Key Laboratory of Translational Oncology, China.
Zitieren
APA
Chen, L. M., Yu, S. C. H., Li, L., Hui, E. P., Yeo, W., & Chan, S. L. (2025). Specific indicators of unsuitability for transarterial chemoembolisation in patients with intermediate-stage hepatocellular carcinoma according to thresholds of tumour burden and liver function as judged by survival benefit over sorafenib. Hong Kong Medical Journal. https://doi.org/10.12809/hkmj2311239
Vancouver
Chen LM, Yu SCH, Li L, Hui EP, Yeo W, Chan SL. Specific indicators of unsuitability for transarterial chemoembolisation in patients with intermediate-stage hepatocellular carcinoma according to thresholds of tumour burden and liver function as judged by survival benefit over sorafenib. Hong Kong Medical Journal. 2025. doi:10.12809/hkmj2311239
BibTeX
@article{Chen2025,
author = {Chen, L M and Yu, S C H and Li, L and Hui, E P and Yeo, W and Chan, S L},
title = {Specific indicators of unsuitability for transarterial chemoembolisation in patients with intermediate-stage hepatocellular carcinoma according to thresholds of tumour burden and liver function as judged by survival benefit over sorafenib},
journal = {Hong Kong Medical Journal},
year = {2025},
doi = {10.12809/hkmj2311239}
}
EUVIMED